Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.22 USD | +0.45% |
|
-11.20% | -42.78% |
06-24 | Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study | MT |
06-24 | Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.78% | 70.73M | |
+16.59% | 45.51B | |
-9.89% | 38.52B | |
+38.08% | 38.13B | |
+27.12% | 30.74B | |
-8.64% | 26.03B | |
+11.81% | 25.92B | |
+45.08% | 14.13B | |
+32.85% | 12.73B | |
-7.19% | 11.29B |
- Stock Market
- Equities
- ANIX Stock
- News Anixa Biosciences, Inc.
- HC Wainwright Adjusts Price Target on Anixa Biosciences to $12 From $11, Keeps Buy Rating